Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Personalis : Needham & Co Adjusts Personalis PT to $28 From $33, Maintains Buy Rating

09/20/2021 | 01:49pm EST


© MT Newswires 2021
All news about PERSONALIS, INC.
11/18Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conferenc..
BU
11/12Personalis Named to Inc.'s 2021 Best-Led Companies List
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th A..
BU
11/11Personalis to Present New Data at the Society for Immunotherapy of Cancer 36th Annual M..
CI
11/08Morgan Stanley Downgrades Personalis to Equalweight from Overweight, Adjusts Price Targ..
MT
11/04Personalis Q3 Net Loss Widens Despite Revenue Growth, Tightens Loss Guidance; Stock Ris..
MT
11/04PERSONALIS : Q3 Earnings Snapshot
AQ
11/04PERSONALIS, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/04Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
11/04Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $22.3M, vs. Street Est of $22.2M
MT
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Financials (USD)
Sales 2021 85,1 M - -
Net income 2021 -67,3 M - -
Net cash 2021 287 M - -
P/E ratio 2021 -8,00x
Yield 2021 -
Capitalization 548 M 548 M -
EV / Sales 2021 3,07x
EV / Sales 2022 5,38x
Nbr of Employees 235
Free-Float 98,1%
Chart PERSONALIS, INC.
Duration : Period :
Personalis, Inc. Technical Analysis Chart | PSNL | US71535D1063 | MarketScreener
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 12,24 $
Average target price 32,00 $
Spread / Average Target 161%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Scientific Officer
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-63.62%597
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745